Evidence map›Paper›PMID 36291008›Full record

ReviewBiosensors2022

Application of Microfluidics in Drug Development from Traditional Medicine.

Xue Li, Xiaoming Fan, Zhu Li, Lina Shi, Jinkuan Liu, Hongzhi Luo, Lijun Wang, Xiaoxin Du, Wenzhu Chen, Jiuchuan Guo and 2 more

Abstract readReview
In one paragraph

Review in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  7. Article
  8. Review
  9. Droplet-Based Microfluidics: Applications in Pharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Droplets microfluidics platform-A tool for single cell research.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xue LiSichuan Hanyuan County People's Hospital, Hanyuan 625300, China.
Xiaoming FanDepartment of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Zhu LiCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Lina ShiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
Jinkuan LiuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China.
Hongzhi LuoDepartment of Laboratory Medicine, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi 563002, China.
Lijun WangDepartment of Ophthalmology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610031, China.
Xiaoxin DuOffice of Scientific Research & Development, University of Electronic Science and Technology, Chengdu 610054, China.
Wenzhu ChenDepartment of Blood Transfusion, The First People's Hospital of Longquanyi District, Chengdu 610041, China.
Jiuchuan GuoThe M.O.E. Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, #1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China.
Chenzhong LiDepartment of Biochemistry and Molecular Biology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0002-0486-4530
Shan LiuSichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While there are many clinical drugs for prophylaxis and treatment, the search for those with low or no risk of side effects for the control of infectious and non-infectious diseases is a dilemma that cannot be solved by today's traditional drug development strategies. The need for new drug development strategies is becoming increasingly important, and the development of new drugs from traditional medicines is the most promising strategy. Many valuable clinical drugs have been developed based on traditional medicine, including drugs with single active ingredients similar to modern drugs and those developed from improved formulations of traditional drugs. However, the problems of traditional isolation and purification and drug screening methods should be addressed for successful drug development from traditional medicine. Advances in microfluidics have not only contributed significantly to classical drug development but have also solved many of the thorny problems of new strategies for developing new drugs from traditional drugs. In this review, we provide an overview of advanced microfluidics and its applications in drug development (drug compound synthesis, drug screening, drug delivery, and drug carrier fabrication) with a focus on its applications in conventional medicine, including the separation and purification of target components in complex samples and screening of active ingredients of conventional drugs. We hope that our review gives better insight into the potential of traditional medicine and the critical role of microfluidics in the drug development process. In addition, the emergence of new ideas and applications will bring about further advances in the field of drug development.

Indexed as

Medicine, TraditionalMicrofluidicsDrug CarriersDrug CompoundingDrug DevelopmentDrug CarriersbioMEMSdrug developmentmicrofluidicstraditional medicine

Identifiers

PMID36291008
PMCPMC9599478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.